Sparks sells regulatory fast pass to Jazz for $110M
Brief:
Spark Therapeutics has sold a priority review voucher (PRV) to Jazz Pharmaceuticals for $110 million, according to a Monday disclosure.
While details wer...
Continue Reading →
